Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy‐proven NASH
- 14 June 2017
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 37 (12) , 1887-1896
Abstract
Background & Aims: The dynamic response of serum fibrosis biomarkers to histological changes within the liver following lifestyle intervention (LI) is unknown. We explored relationships between changes in serum biomarkers and liver fibrosis in NASH patients undergoing LI.Methods: Paired liver biopsies were performed in 261 NASH patients to assess fibrosis change after 1 year of LI. We explored the utility of serum fibrosis markers to predict changes in hepatic fibrosis and developed and internally validated a model for predicting fibrosis improvement in patients with baseline fibrosis.Results: Regression, stabilization and worsening of fibrosis occurred in 51 (20%), 165 (63%) and 45 (17%) patients respectively. By multivariable analysis, change in HbA1c (OR, 0.39, P<.01), platelets (OR, 1.22, P<.01) and NFS (OR, 0.27, P<.01), as well as ALT normalization (OR, 9.7, P<.01) were independently associated with fibrosis improvement, whereas change in platelets (OR, 0.96, P<.01), and NFS (OR, 1.8, P<.01) as well as ALT normalization (OR, 0.21, P<.01) were linked to fibrosis progression. A model, including change in HbA1c, platelet and ALT normalization, was significantly more accurate (AUC of 0.96, 95% CI, l0.94‐0.99) than NFS, FIB‐4 and APRI for predicting fibrosis improvement. Using a threshold of ≥0.497, positive and negative predictive values were 94% (95% CI, 84‐98) and 91% (95% CI, 81‐96) respectively.Conclusions: Change in NFS, platelets and ALT normalization are associated with change in liver fibrosis after 1 year of LI. A model including change in HbA1c, platelet and ALT normalization discriminated patients with fibrosis improvement significantly better than other biomarkers.Keywords
Funding Information
- Ministry of Health (ING‐CITMA‐2009)
This publication has 34 references indexed in Scilit:
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic SteatohepatitisGastroenterology, 2015
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosisJournal of Hepatology, 2015
- Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint WorkshopHepatology, 2014
- Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2014
- Noninvasive evaluation of NAFLDNature Reviews Gastroenterology & Hepatology, 2013
- Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisalJournal of Hepatology, 2013
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of GastroenterologyGastroenterology, 2012
- Effects of Liver Biopsy Sample Length and Number of Readings on Sampling Variability in Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- Liver biopsy†Hepatology, 2009
- Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver DiseaseGastroenterology, 2005